Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label NUC-1031 in platinum-resistant ovarian cancer
2016-003287-39Phase 2Terminated
- Sponsor
- NuCana
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pracinostat in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by NuCana. Primary endpoint: Objective response rate. Started Mar 2017; status: terminated.
02
Drugs
pracinostat
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2016-003287-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003287-39.